Peptide LocalCompare price, evidence & access
Search /Compare vendors
Home/Peptide database
Evidence-linked peptide database

Peptide database.
Status, evidence, prices.

Search 40 peptide records and 139 aliases across FDA-approved medicines, drugs in clinical trials, and US research peptide price boards. Every result includes a current status, checked date, category boundary, and primary source.

New to the category? Start with “What are peptides?” →
Looking for benefits, risks, cost, or a provider? Open the peptide therapy field manual →

ByPeptide Local Editorial DeskUpdated July 17, 2026How we review
40published entity records
139searchable aliases and codes
12research, medicine, and pipeline families
211evidence references across profiles
Peptide evidence navigator

Choose a name. Ask one clear question.

Get the status, FDA boundary, linked clinical trials, evidence coverage, price-comparison route, country map, or next comparison for any published record. Every answer keeps approved medicines, clinical programs, and research seller data separate.

2. Choose your question
Clinical pipeline profileChecked July 20, 2026

Direct answer

What is the current status of Retatrutide?

Retatrutide is filed here as an investigational clinical program sponsored by Eli Lilly and Company. Its current record is Phase 3 program reporting results, with gip + glp-1 + glucagon receptor agonist · once-weekly subcutaneous injection. Investigational status is not retail approval.
This category can answer
Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program?
It cannot establish
Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.

This tool routes evidence; it does not diagnose, prescribe, rank clinical benefit, or certify a seller. Record count is coverage, not an evidence-strength score.

The status map

One index does not mean one comparison.

Research listings, approved medicines, and clinical development answer different questions. The database makes all three discoverable while keeping their evidence, schema, and commercial boundaries separate.

Lane 0120 records

Research market boards

Exact-size public seller observations with list price, availability, document access, shipping language, and a checked date.

Answers
What did public US research catalogs show?
Does not answer
Clinical safety, approval, dose, or treatment suitability.
Browse price comparisons →
Lane 027 records

Approved medicine records

Exact brand, active ingredient, FDA application, labeled use, presentation, and current DailyMed record for regulated prescription products.

Answers
Which exact product and label did FDA approve?
Does not answer
Individual suitability, a treatment choice, or equivalence to compounded or research products.
Browse approved medicines →
Lane 0313 records

Clinical pipeline profiles

Sponsor, registry, trial, phase, mechanism, result, and regulatory records for investigational obesity and metabolic programs.

Answers
What has been studied and what is the current development record?
Does not answer
Approval, launch date, individual benefit, or online-vial legitimacy.
Browse clinical pipeline →
Category checkpoint≠

Same name does not mean same product, route, evidence, or legal status.

Open safety map ↗
Search the published record

One name search. Three evidence lanes.

Search exact names, former names, sponsor codes, aliases, families, mechanisms, or routes. A result opens the correct market, medicine, or clinical record; the lanes never merge.

40records shown
01Research price board

AOD-9604

AOD 9604 · AOD9604 · Tyr-hGH 177-191

Family
Growth-signaling analogues
Comparison
5 mg like-for-like comparison
Current record
3 of 4 rows in stock
Coverage
4 seller records

Synthetic human growth hormone fragment research material

02Research price board

BPC-157

Body Protection Compound 157 · BPC 157

Family
Tissue and thymic peptides
Comparison
10 mg like-for-like comparison
Current record
5 of 7 rows in stock
Coverage
7 seller records

Synthetic pentadecapeptide research material

03Clinical pipeline profile

Cagrilintide

AM833 · NNC0174-0833

Family
Obesity and metabolic pipeline
Sponsor
Novo Nordisk
Current record
Phase 3 monotherapy program
Coverage
7 cited records

Long-acting amylin analogue · Once-weekly subcutaneous injection

04Clinical pipeline profile

CagriSema

cagrilintide + semaglutide · REDEFINE 1 · REIMAGINE 1-3

Family
Obesity and metabolic pipeline
Sponsor
Novo Nordisk
Current record
Phase 3 / US regulatory review
Coverage
8 cited records

Amylin analogue + GLP-1 receptor agonist · Once-weekly subcutaneous injection

05Research price board

CJC-1295 DAC

CJC-1295 with DAC · CJC 1295 DAC · DAC:GRF

Family
Growth-signaling analogues
Comparison
5 mg like-for-like comparison
Current record
2 of 3 rows in stock
Coverage
3 seller records

Drug-affinity-complex growth hormone-releasing factor analogue research material

06Research price board

CJC-1295 no DAC

Modified GRF 1-29 · Mod GRF 1-29 · CJC 1295 without DAC

Family
Growth-signaling analogues
Comparison
5 mg like-for-like comparison
Current record
2 of 3 rows in stock
Coverage
3 seller records

Modified growth hormone-releasing factor analogue research material

07Research price board

DSIP

Delta sleep-inducing peptide · Emideltide · DSIP nonapeptide

Family
Neuropeptides
Comparison
5 mg like-for-like comparison
Current record
2 of 3 rows in stock
Coverage
3 seller records

Synthetic delta sleep-inducing nonapeptide research material

08Clinical pipeline profile

Ecnoglutide

XW003 · Sciwind ecnoglutide · cAMP-biased GLP-1 receptor agonist · 埃诺格鲁肽

Family
Obesity and metabolic pipeline
Sponsor
Sciwind Biosciences; Pfizer commercialization partner in Mainland China
Current record
China approvals active; indication-expansion studies continue
Coverage
8 cited records

cAMP-signalling-biased GLP-1 receptor agonist · Once-weekly subcutaneous injection

09FDA-approved medicine

EGRIFTA WR (Tesamorelin)

tesamorelin · Egrifta WR · Egrifta SV · TH9507 · BLA 022505 · GHRF analog

Family
FDA-approved GHRF-analog medicine
Label company
Theratechnologies Inc.
Current record
BLA 022505 · FDA-approved prescription drug
Coverage
2 primary regulatory records

Lyophilized powder kit · Subcutaneous

10Clinical pipeline profile

Eloralintide

LY3841136 · eloralintide peptide · selective amylin receptor agonist

Family
Obesity and metabolic pipeline
Sponsor
Eli Lilly and Company
Current record
Phase 3 ENLIGHTEN program recruiting
Coverage
9 cited records

Selective amylin 1 receptor agonist · Once-weekly subcutaneous injection

11Clinical pipeline profile

Enicepatide

CT-388 · RO7795068 · RG6640

Family
Obesity and metabolic pipeline
Sponsor
Roche / Carmot Therapeutics
Current record
Phase 3 ENITH program recruiting
Coverage
6 cited records

Signal-biased GLP-1 + GIP receptor dual agonist · Once-weekly subcutaneous injection

12FDA-approved medicine

FOUNDAYO (Orforglipron)

orforglipron · Foundayo · LY3502970 · NDA 220934 · oral GLP-1 · nonpeptide GLP-1 · non-peptide GLP-1 · weight loss pill

Family
FDA-approved non-peptide GLP-1 comparator
Label company
Lilly USA, LLC
Current record
NDA 220934 · FDA-approved prescription drug
Coverage
6 primary regulatory records

Film-coated tablets · Oral

13Research price board

GHK-Cu

Copper tripeptide · GHK Cu · Copper tripeptide-1 · Prezatide copper

Family
Copper and short peptides
Comparison
100 mg like-for-like comparison
Current record
3 of 5 rows in stock
Coverage
5 seller records

Copper tripeptide research material

14Research price board

IGF-1 LR3

Long R3 IGF-1 · Insulin-like growth factor long chain R3 · 100 mcg IGF-1 LR3

Family
Growth-signaling analogues
Comparison
0.1 mg like-for-like comparison
Current record
1 of 3 rows in stock
Coverage
3 seller records

Long-arginine-3 insulin-like growth factor analogue research reagent

15Research price board

Ipamorelin

NNC 26-0161 · growth hormone secretagogue

Family
Growth-signaling analogues
Comparison
10 mg like-for-like comparison
Current record
3 of 3 rows in stock
Coverage
3 seller records

Synthetic growth hormone secretagogue research material

16Research price board

Kisspeptin-10

Kisspeptin 10 · Kp-10 · Metastin fragment · KISS1 decapeptide

Family
Reproductive-signaling peptides
Comparison
10 mg like-for-like comparison
Current record
2 of 3 rows in stock
Coverage
3 seller records

Synthetic kisspeptin decapeptide research material

17Clinical pipeline profile

MariTide

maridebart cafraglutide · AMG 133

Family
Obesity and metabolic pipeline
Sponsor
Amgen
Current record
Phase 3 program active
Coverage
4 cited records

GLP-1 receptor agonist + GIP receptor antagonist · Subcutaneous injection

18Clinical pipeline profile

Mazdutide

IBI362 · LY3305677 · GLP-1/glucagon dual agonist

Family
Obesity and metabolic pipeline
Sponsor
Innovent Biologics; licensed from Eli Lilly for China
Current record
China approvals active; Phase 3 and indication-expansion studies continue
Coverage
10 cited records

GLP-1 and glucagon receptor dual agonist · Once-weekly subcutaneous injection

19Research price board

Melanotan I

MT-I · MT1 · Afamelanotide · Melanotan 1

Family
Melanocortin analogues
Comparison
10 mg like-for-like comparison
Current record
2 of 3 rows in stock
Coverage
3 seller records

Synthetic linear alpha-melanocyte-stimulating hormone analogue research material

20Research price board

Melanotan II

MT-II · MT2 · Melanotan 2

Family
Melanocortin analogues
Comparison
10 mg like-for-like comparison
Current record
1 of 3 rows in stock
Coverage
3 seller records

Synthetic cyclic melanocortin analogue research material

21Research price board

MOTS-c

MOTS c · Mitochondrial open reading frame peptide

Family
Mitochondrial and metabolic
Comparison
10 mg like-for-like comparison
Current record
5 of 7 rows in stock
Coverage
7 seller records

Mitochondria-derived peptide research material

22Research price board

NAD+

Nicotinamide adenine dinucleotide · NAD plus

Family
Mitochondrial and metabolic
Comparison
1000 mg like-for-like comparison
Current record
3 of 4 rows in stock
Coverage
4 seller records

Dinucleotide coenzyme research material (not a peptide)

23Clinical pipeline profile

Pemvidutide

ALT-801 · balanced GLP-1/glucagon dual agonist · Altimmune pemvidutide

Family
Obesity and metabolic pipeline
Sponsor
Altimmune
Current record
Phase 2 programs active; MASH Phase 3 planned
Coverage
9 cited records

Balanced 1:1 GLP-1 and glucagon receptor dual agonist · Once-weekly subcutaneous injection

24Clinical pipeline profile

Petrelintide

ZP8396 · long-acting amylin analogue

Family
Obesity and metabolic pipeline
Sponsor
Zealand Pharma + Roche
Current record
Phase 3 planned; Phase 2 program active
Coverage
5 cited records

Long-acting amylin analogue · Once-weekly subcutaneous injection

25Research price board

PT-141 (Bremelanotide)

PT 141 · Bremelanotide · Vyleesi

Family
Melanocortin analogues
Comparison
10 mg like-for-like comparison
Current record
2 of 3 rows in stock
Coverage
3 seller records

Synthetic melanocortin-receptor agonist research material

26Clinical pipeline profile

Retatrutide

LY3437943 · triple agonist · reta · reta peptide

Family
Obesity and metabolic pipeline
Sponsor
Eli Lilly and Company
Current record
Phase 3 program reporting results
Coverage
4 cited records

GIP + GLP-1 + glucagon receptor agonist · Once-weekly subcutaneous injection

27FDA-approved medicine

SAXENDA (Liraglutide)

liraglutide · Saxenda · NN2211 · NDA 206321 · GLP-1 receptor agonist

Family
FDA-approved incretin medicine
Label company
Novo Nordisk Inc.
Current record
NDA 206321 · FDA-approved prescription drug
Coverage
2 primary regulatory records

Injection · Subcutaneous

28FDA-approved medicine

SCENESSE (Afamelanotide)

afamelanotide · Scenesse · CUV1647 · NDA 210797 · alpha-MSH analog

Family
FDA-approved melanocortin medicine
Label company
CLINUVEL INC.
Current record
NDA 210797 · FDA-approved prescription drug
Coverage
2 primary regulatory records

Implant · Subcutaneous

29Research price board

Selank

TP-7 · selank acetate

Family
Neuropeptides
Comparison
10 mg like-for-like comparison
Current record
2 of 3 rows in stock
Coverage
3 seller records

Synthetic heptapeptide research material

30Research price board

Semax

ACTH(4-7)-PGP · MEHFPGP · Semax heptapeptide

Family
Neuropeptides
Comparison
10 mg like-for-like comparison
Current record
3 of 3 rows in stock
Coverage
3 seller records

Synthetic ACTH-fragment analogue research material

31Research price board

Sermorelin

GHRH 1-29 · Sermorelin acetate · Geref

Family
Growth-signaling analogues
Comparison
5 mg like-for-like comparison
Current record
2 of 3 rows in stock
Coverage
3 seller records

Synthetic growth hormone-releasing hormone fragment research material

32Clinical pipeline profile

Survodutide

BI 456906 · glucagon/GLP-1 dual agonist

Family
Obesity and metabolic pipeline
Sponsor
Boehringer Ingelheim + Zealand Pharma
Current record
Phase 3 program active and reporting
Coverage
7 cited records

Glucagon + GLP-1 receptor dual agonist · Once-weekly subcutaneous injection

33Research price board

TB-500

Thymosin beta-4 fragment · TB500

Family
Tissue and thymic peptides
Comparison
10 mg like-for-like comparison
Current record
5 of 7 rows in stock
Coverage
7 seller records

Thymosin beta-4 research material

34Research price board

Tesamorelin

Egrifta · TH9507

Family
Growth-signaling analogues
Comparison
10 mg like-for-like comparison
Current record
4 of 5 rows in stock
Coverage
5 seller records

Synthetic growth hormone-releasing factor analog research material

35Research price board

Thymosin Alpha-1

Thymalfasin · TA1 · Thymosin alpha 1

Family
Tissue and thymic peptides
Comparison
5 mg like-for-like comparison
Current record
2 of 3 rows in stock
Coverage
3 seller records

Synthetic 28-amino-acid thymic peptide research material

36Clinical pipeline profile

VK2735

Viking VK2735 · oral VK2735 · GLP-1/GIP dual agonist

Family
Obesity and metabolic pipeline
Sponsor
Viking Therapeutics
Current record
Subcutaneous Phase 3 active; oral Phase 3 planned
Coverage
8 cited records

GIP and GLP-1 receptor dual agonist · Once-weekly subcutaneous injection and once-daily oral tablet

37FDA-approved medicine

VYLEESI (Bremelanotide)

bremelanotide · Vyleesi · PT-141 · NDA 210557 · melanocortin receptor agonist

Family
FDA-approved melanocortin medicine
Label company
Cosette Pharmaceuticals, Inc.
Current record
NDA 210557 · FDA-approved prescription drug
Coverage
2 primary regulatory records

Injection · Subcutaneous

38FDA-approved medicine

WEGOVY (Semaglutide)

semaglutide · Wegovy · NDA 215256 · GLP-1 receptor agonist · semaglutide injection · semaglutide tablets · oral Wegovy · Wegovy pill · sémaglutide · semaglutida · Semaglutid · 司美格鲁肽

Family
FDA-approved incretin medicine
Label company
Novo Nordisk Inc.
Current record
NDA 215256 · FDA-approved prescription drug
Coverage
7 primary regulatory records

Injection and tablets · Subcutaneous and oral

39Clinical pipeline profile

Zenagamtide

amycretin · NNC0487-0111 · AMAZE 7

Family
Obesity and metabolic pipeline
Sponsor
Novo Nordisk
Current record
Phase 3 development underway
Coverage
5 cited records

GLP-1 + amylin receptor agonist · Once-daily oral or once-weekly subcutaneous

40FDA-approved medicine

ZEPBOUND (Tirzepatide)

tirzepatide · Zepbound · LY3298176 · NDA 217806 · GIP and GLP-1 receptor agonist

Family
FDA-approved incretin medicine
Label company
Lilly USA, LLC
Current record
NDA 217806 · FDA-approved prescription drug
Coverage
2 primary regulatory records

Injection · Subcutaneous

Worldwide, province, and state maps

41 names across 42 countries, 10 Canadian provinces, and 50 US states.

Each map resolves the compound identity first, then connects it to localized country answers, official Canadian province routes, or US state pharmacy records without merging evidence categories.

Identity resolution

The searches most likely to cross a category line.

These name clusters are kept visible because aliases, sponsor codes, combinations, and approved-product names can send readers to the wrong evidence record.

03Cagrilintide · CagriSema

One component is not the fixed-dose combination.

Cagrilintide has its own investigational program. CagriSema combines cagrilintide with semaglutide and therefore has a separate evidence record, trial program, and regulatory path.

Open cagrilintide profile Open CagriSema profile
04Amycretin · zenagamtide · NNC0487-0111

A development name can change while the evidence trail continues.

The pipeline profile keeps the former name, current nonproprietary name, and sponsor code together so older trial coverage resolves to the same dated program record.

Open zenagamtide / amycretin profile
05MariTide · maridebart cafraglutide · AMG 133

Brand-like shorthand, generic name, and sponsor code can point together.

All three names route to one investigational profile, where monthly evidence, quarterly-maintenance evidence, Phase 3 status, and unresolved claims stay attached to their sources.

Open MariTide profile
Peptide database FAQ

Direct answers to the questions behind the search.

These answers define what the database can verify, where the category changes, and which record to open next.

01

What is in the Peptide Local peptide database?

The database contains 40 source-linked records in three separate categories: 7 exact FDA-approved medicine records, 13 investigational clinical programs, and 20 dated US research-market price boards. It also resolves 139 alternate names, sponsor codes, application numbers, and common search terms.

02

Which peptides are FDA approved?

FDA approval belongs to an exact medicine, application, label, dosage form, route, and approved use. Use the approved-medicine lane to verify records such as WEGOVY, ZEPBOUND, SAXENDA, VYLEESI, SCENESSE, EGRIFTA WR, and FOUNDAYO. A similar ingredient name, compounded product, or research vial does not inherit that approval.

03

Is retatrutide FDA approved?

No. Retatrutide is tracked as an investigational Eli Lilly clinical program, not an FDA-approved retail medicine. Its profile links the current development phase, mechanism, trial records, reported findings, checked date, and unresolved questions without converting clinical research into a launch or approval claim.

04

Can I compare research peptide prices?

Yes, when the compound name, nominal size, seller market, visible list price, availability signal, and checked date match. Peptide Local currently maintains 20 exact-size research price boards. Price and seller-document access still do not prove identity, purity, quantity, sterility, safety, legality, or suitability for use.

05

Where can I buy peptides?

Start by identifying the category. An FDA-approved medicine requires the appropriate prescription and a licensed pharmacy route. A research-market listing is not a treatment-shopping substitute and should be assessed through exact seller identity, destination rules, current stock, landed cost, lot documentation, and source dates. Peptide Local compares public claims but does not certify a seller as safe.

06

How do I check a peptide in another country?

Resolve the exact ingredient, medicine, or clinical program first, then check the destination country's official product database and its separate pharmacy, seller, establishment, or supply records. A US approval, clinical status, or research listing does not transfer worldwide. The database links every covered name to a 42-country verification map.

Coverage rule

Published evidence, not an endless peptide-name dump.

This database currently includes every qualified Peptide Local price board, every published approved-medicine record, and every maintained pipeline profile. An entity is added only when it has a substantive internal record, a dated evidence trail, searchable aliases, and a category-safe destination.

Absence from the database does not establish that a substance is safe, unsafe, legal, illegal, approved, or unapproved. It means Peptide Local has not yet published a record that clears the relevant evidence gate.

Check a peptide by destination country →Download the open peptide evidence and status index →Download the 1722-row global country dataset →Download the 2050-row US state dataset →Download the 410-row Canada province dataset →Download the 328-row Australia jurisdiction dataset →Read the publication gates →Audit the source registry →